Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens

John P. Welsh, Yuan Lu, Xiaosong He, Harry B. Greenberg, James R. Swartz

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

In order to effectively combat pandemic influenza threats, there is a need for more rapid and robust vaccine production methods. In this article, we demonstrate E. coli-based cell-free protein synthesis (CFPS) as a method to rapidly produce domains from the protein hemagglutinin (HA), which is present on the surface of the influenza virus. The portion of the HA coding sequence for the "head" domain from the 2009 pandemic H1N1 strain was first optimized for E. coli expression. The protein domain was then produced in CFPS reactions and purified in soluble form first as a monomer and then as a trimer by a C-terminal addition of the T4 bacteriophage foldon domain. Production of soluble trimeric HA head domain was enhanced by introducing stabilizing amino acid mutations to the construct in order to avoid aggregation. Trimerization was verified using size exclusion HPLC, and the stabilized HA head domain trimer was more effectively recognized by antibodies from pandemic H1N1 influenza vaccine recipients than was the monomer and also bound to sialic acids more strongly, indicating that the trimers are correctly formed and could be potentially effective as vaccines.

Original languageEnglish (US)
Pages (from-to)2962-2969
Number of pages8
JournalBiotechnology and Bioengineering
Volume109
Issue number12
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Vaccines
Hemagglutinins
Antigens
Human Influenza
Pandemics
Proteins
Escherichia coli
Monomers
Sialic Acids
Bacteriophage T4
Bacteriophages
Influenza Vaccines
Orthomyxoviridae
Viruses
Antibodies
Amino acids
Agglomeration
Head
High Pressure Liquid Chromatography
Amino Acids

Keywords

  • Cell-free protein synthesis
  • Hemagglutinin
  • Influenza
  • Trimer

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens. / Welsh, John P.; Lu, Yuan; He, Xiaosong; Greenberg, Harry B.; Swartz, James R.

In: Biotechnology and Bioengineering, Vol. 109, No. 12, 12.2012, p. 2962-2969.

Research output: Contribution to journalArticle

Welsh, John P. ; Lu, Yuan ; He, Xiaosong ; Greenberg, Harry B. ; Swartz, James R. / Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens. In: Biotechnology and Bioengineering. 2012 ; Vol. 109, No. 12. pp. 2962-2969.
@article{90c88e8cd2e643409e20d53b2e26dfe0,
title = "Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens",
abstract = "In order to effectively combat pandemic influenza threats, there is a need for more rapid and robust vaccine production methods. In this article, we demonstrate E. coli-based cell-free protein synthesis (CFPS) as a method to rapidly produce domains from the protein hemagglutinin (HA), which is present on the surface of the influenza virus. The portion of the HA coding sequence for the {"}head{"} domain from the 2009 pandemic H1N1 strain was first optimized for E. coli expression. The protein domain was then produced in CFPS reactions and purified in soluble form first as a monomer and then as a trimer by a C-terminal addition of the T4 bacteriophage foldon domain. Production of soluble trimeric HA head domain was enhanced by introducing stabilizing amino acid mutations to the construct in order to avoid aggregation. Trimerization was verified using size exclusion HPLC, and the stabilized HA head domain trimer was more effectively recognized by antibodies from pandemic H1N1 influenza vaccine recipients than was the monomer and also bound to sialic acids more strongly, indicating that the trimers are correctly formed and could be potentially effective as vaccines.",
keywords = "Cell-free protein synthesis, Hemagglutinin, Influenza, Trimer",
author = "Welsh, {John P.} and Yuan Lu and Xiaosong He and Greenberg, {Harry B.} and Swartz, {James R.}",
year = "2012",
month = "12",
doi = "10.1002/bit.24581",
language = "English (US)",
volume = "109",
pages = "2962--2969",
journal = "Biotechnology and Bioengineering",
issn = "0006-3592",
publisher = "Wiley-VCH Verlag",
number = "12",

}

TY - JOUR

T1 - Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens

AU - Welsh, John P.

AU - Lu, Yuan

AU - He, Xiaosong

AU - Greenberg, Harry B.

AU - Swartz, James R.

PY - 2012/12

Y1 - 2012/12

N2 - In order to effectively combat pandemic influenza threats, there is a need for more rapid and robust vaccine production methods. In this article, we demonstrate E. coli-based cell-free protein synthesis (CFPS) as a method to rapidly produce domains from the protein hemagglutinin (HA), which is present on the surface of the influenza virus. The portion of the HA coding sequence for the "head" domain from the 2009 pandemic H1N1 strain was first optimized for E. coli expression. The protein domain was then produced in CFPS reactions and purified in soluble form first as a monomer and then as a trimer by a C-terminal addition of the T4 bacteriophage foldon domain. Production of soluble trimeric HA head domain was enhanced by introducing stabilizing amino acid mutations to the construct in order to avoid aggregation. Trimerization was verified using size exclusion HPLC, and the stabilized HA head domain trimer was more effectively recognized by antibodies from pandemic H1N1 influenza vaccine recipients than was the monomer and also bound to sialic acids more strongly, indicating that the trimers are correctly formed and could be potentially effective as vaccines.

AB - In order to effectively combat pandemic influenza threats, there is a need for more rapid and robust vaccine production methods. In this article, we demonstrate E. coli-based cell-free protein synthesis (CFPS) as a method to rapidly produce domains from the protein hemagglutinin (HA), which is present on the surface of the influenza virus. The portion of the HA coding sequence for the "head" domain from the 2009 pandemic H1N1 strain was first optimized for E. coli expression. The protein domain was then produced in CFPS reactions and purified in soluble form first as a monomer and then as a trimer by a C-terminal addition of the T4 bacteriophage foldon domain. Production of soluble trimeric HA head domain was enhanced by introducing stabilizing amino acid mutations to the construct in order to avoid aggregation. Trimerization was verified using size exclusion HPLC, and the stabilized HA head domain trimer was more effectively recognized by antibodies from pandemic H1N1 influenza vaccine recipients than was the monomer and also bound to sialic acids more strongly, indicating that the trimers are correctly formed and could be potentially effective as vaccines.

KW - Cell-free protein synthesis

KW - Hemagglutinin

KW - Influenza

KW - Trimer

UR - http://www.scopus.com/inward/record.url?scp=84868091682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868091682&partnerID=8YFLogxK

U2 - 10.1002/bit.24581

DO - 10.1002/bit.24581

M3 - Article

C2 - 22729608

AN - SCOPUS:84868091682

VL - 109

SP - 2962

EP - 2969

JO - Biotechnology and Bioengineering

JF - Biotechnology and Bioengineering

SN - 0006-3592

IS - 12

ER -